课题基金 / 基金详情

SAFETY AND EFFICACY OF HYDROXYUREA AS A PROPHYLACTIC THERAPY FOR SICKLE CELL

SAFETY AND EFFICACY OF HYDROXYUREA AS A PROPHYLACTIC THERAPY FOR SICKLE CELL
羟基脲作为镰状细胞预防疗法的安全性和有效性
批准号:
7377385
负责人:
Eugene P Orringer
金额:
$0.17万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-12-01 至 2006-11-30

项目摘要

项目成果

Eugene P Orringer的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this double-blind, randomized study is: a) to compare the clinical course of patients receiving hydroxyurea to a control group receiving placebo and; b) to quantitate the effect of hydroxyurea on fetal hemoglobin production in the red blood cells of patients with sickle cell anemia.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PERMEABILITY & METABOLISM OF RBC FROM PATIENTS WITH HEMOLYTIC ANEMIAS
CLINICAL TRIAL: NEUROPSYCHOLOGICAL DYSFUNCTION AND NEUROIMAGING ABNORMALITIES IN
NEUROPSYCHOLOGICAL DYSFUNCTION AND NEUROIMAGING ABNORMALITIES IN SCD
PERMEABILITY & METABOLISM OF RBC FROM PATIENTS WITH HEMOLYTIC ANEMIAS
海外基金